The Therapeutic Effect of Colchicine on Delayed Pulmonary Injury of Sulfur Mustard in Animal Model

Document Type : Original Article(s)

Authors

1 Assistant Professor, Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 General Practitionere, East Sage Investigative Corporation, Isfahan Science and Technology Town, Isfahan, Iran

3 General Practitionere, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Among late complications of sulfur mustard gas, respiratory problems, especially chronic bronchitis and pulmonary fibrosis, are the greatest causes of long-term disability. Colchicine has anti-inflammatory effects and also indication of its usage in pulmonary fibrosis. According to these and note to the effect of oxidative stress in pathogenesis of chronic bronchitis and pulmonary fibrosis, the therapeutic effects of Cochicine and the role of oxidative stress in its mechanism was studied.Methods: One group of mice that had inhaled sulfur mustard one month ego was treated by colchicine. After sacrificing and sampling, biochemical indeces of chronic inflammation and pulmonary fibrosis of experimental group was compared with positive and negative control groups.Finding: A significant decrease was seen in alveolar space percentage, serum vitamin C, and catalase and an increase was seen in hydroxylproline concentration, lymphocyte infiltration, and serum H2O2 in positive control group in comparison with negative control. Vitamin C and catalase increase and hydroxylproline concentration, lymphocyte infiltration and serum H2O2 decrease in experimental group in comparison with positive control group were obtained.Conclusion: Colchicine has therapeutic effects on delayed lung complications of sulfur mustard gas injury and diminishing the oxidative stress can be one of mechanisms of this drugs.

Keywords

References

  1. Balali-Mood M, Hefazi M. The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning. Fundam Clin Pharmacol 2005; 19(3): 297-315.
  2. Papirmeister B. Medical defense against mustard gas: toxic mechanisms and pharmacological implications. New York: CRC Press; 1991. p. 108-99.
  3. Meier HL, Millard CB. Alterations in human lymphocyte DNA caused by sulfur mustard can be mitigated by selective inhibitors of poly (ADP-ribose) polymerase. Biochim Biophys Acta 1998; 1404(3): 367-76.
  4. Moser J, Meier HL. Comparison of cell in sulfur mustard- induced death of keratocytes and lymphocytes. J Appl Toxicol 2000; 1: 23-30.
  5. Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. Incidence of lung, eye, and skin le-sions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med 2003; 45(11): 1136-43.
  6. Mitchell RN, Cotran RC. Cell injury, adaptation and death. In: Kumar V, Cotran R, Robbins SL, Editors. Robbins Basic pathology. Philadelphia: Saunders; 2003. p. 9-11.
  7. Emad A, Rezaian GR. Immunoglobulins and cellular constituents of the BAL fluid of pa-tients with sulfur mustard gas-induced pulmonary fibrosis. Chest 1999; 115(5): 1346-51.
  8. Aghanouri R, Ghanei M, Aslani J, Keivani-Amine H, Rastegar F, Karkhane A. Fibrogenic cytokine levels in bronchoalveolar lavage aspirates 15 years after exposure to sulfur mustard. Am J Physiol Lung Cell Mol Physiol 2004; 287(6): L1160-L1164.
  9. Wagner W, Khanna P, Furst DE. Nonsteroidal anti inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics & drugs used in gout. In: Katzung BG, Editor. Basic & clinical pharmacology. New York: Lange Medical Books/McGraw Hill; 2004. p. 597.
  10. Talmadge E, King JR, Schwarz MI. Idiopathic Interstitial pneumonia. In: Murray JF, Editor. Textbook of respiratory medicine. Phila-delphia: Saunders, 2000. p. 1680-3.
  11. Ozdemir BH, Ozdemir FN, Sezer S, Sar A, Haberal M. Does colchicine have an antifibrotic effect on development of interstitial fibrosis in renal allografts of recipients with familial Mediterranean fever? Transplant Proc 2006; 38(2): 473-6.
  12. Woessner JF. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961; 93: 440-7.
  13. Wolff SP. Ferrousion oxidation in presence of ferric ion indicator xylend orange for measure of hydroperoxides. In: Packer L, Editor. Methods in enzymology. - 300: Oxidants and antioxidants. San Diego: Academic Press; 1994. p. 183-6.
  14. Roe JH, Kuether CA. The determination of ascorbic acid in whole blood and urine through the 2,4-dinitrophenylhydrazine derivative of dehydroascorbic acid. J Biol Chem 1943; 147: 399-407.
  15. Aebi H. Catalase in vitro. Methods Enzymol 1984; 105: 121-6.
  16. Emad A, Rezaian GR. The diversity of the ef-fects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. Chest 1997; 112(3): 734-8.
  17. Hoesel LM, Flierl MA, Niederbichler AD, Rit-tirsch D, McClintock SD, Reuben JS, et al. Ability of antioxidant liposomes to prevent acute and progressive pulmonary injury. Antioxid Redox Signal 2008; 10(5): 973-81.
  18. Emad A, Emad Y. Increased granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) levels in BAL fluid from patients with sulfur mustard gas-induced pulmonary fibrosis. J Aerosol Med 2007; 20(3): 352-60.
  19. Emad A, Emad Y. Relationship between eosinophilia and levels of chemokines (CCL5 and CCL11) and IL-5 in bronchoalveolar lavage fluid of patients with mustard gas-induced pulmonary fibrosis. J Clin Immunol 2007; 27(6): 605-12.
  20. Emad A, Emad Y. Levels of cytokine in bron-choalveolar lavage (BAL) fluid in patients with pulmonary fibrosis due to sulfur mustard gas inhalation. J Interferon Cytokine Res 2007; 27(1): 38-43.
  21. Balali-Mood M, Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol 2006; 99(4): 273-82.
  22. Hefazi M, Attaran D, Mahmoudi M, Balali-Mood M. Late respiratory complications of mustard gas poisoning in Iranian veterans. Inhal Toxicol 2005; 17(11): 587-92.
  23. Ghanei M, Mokhtari M, Mohammad MM, Aslani J. Bronchiolitis obliterans following exposure to sulfur mustard: chest high resolution computed tomography. Eur J Radiol 2004; 52(2): 164-9.
  24. Ghanei M, Tazelaar HD, Chilosi M, Harandi AA, Peyman M, Akbari HM, et al. An interna-tional collaborative pathologic study of surgical lung biopsies from mustard gas-exposed patients. Respir Med 2008; 102(6): 825-30.
  25. Ghanei M, Panahi Y, Mojtahedzadeh M, Khalili AR, Aslani J. Effect of gamma interferon on lung function of mustard gas exposed patients, after 15 years. Pulm Pharmacol Ther 2006; 19(2): 148-53.
  26. Ghanei M, Shohrati M, Harandi AA, Eshraghi M, Aslani J, Alaeddini F, et al. Inhaled cortico-steroids and long-acting beta 2-agonists in treatment of patients with chronic bronchiolitis following exposure to sulfur mustard. Inhal Toxicol 2007; 19(10): 889-94.
  27. Mayes PA, Botham KM. Biologic oxidation. In: Murray RK, Granner DK, Mayes PA, Rodwell VW, Editors. Harper's illustrated Biochemistry. New York: Mc Graw-Hill companies, 2003. p. 91.
  28. Buczynski A, Gnitecki W. Effect of mustard gas on supraoxide dismutase activity and the level of malonyl dialdehyde: in vitro studies. Int J Occup Med Environ Health 1999; 12(2): 119-22.
  29. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 2001; 280(1): C53-C60.
  30. Mourelle M, Fraginals R, Rodriguez L, Favari L, Perez-Alvarez V. Protective effect of col-chiceine against acute liver damage. Life Sci 1989; 45(10): 891-900.
  31. Muriel P, Suarez OR. Role of lipid perox-idation in biliary obstruction in the rat. J Appl Toxicol 1994; 14(6): 423-6.
  32. Das D, Pemberton PW, Burrows PC, Gordon C, Smith A, McMahon RF, et al. Antioxidant properties of colchicine in acute carbon tetrachloride induced rat liver injury and its role in the resolution of established cirrhosis. Biochim Biophys Acta 2000; 1502(3): 351-62.
  33. Peterson TC, Isbrucker RA, Hooper ML. In vitro effect of platelet-derived growth factor on fibroproliferation and effect of cytokine antagonists. Immunopharmacology 1994; 28(3): 259-20.
  34. Entzian P, Schlaak M, Seitzer U, Bufe A, Acil Y, Zabel P. Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung 1997; 175(1): 41-51.
  35. Rennard SI, Bitterman PB, Ozaki T, Rom WN, Crystal RG. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro. The basis of a possible therapeutic approach ot the fibrotic disorders. Am Rev Respir Dis 1988; 137(1): 181-5.
  36. Diegelmann RF, Peterkofsky B. Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. Proc Natl Acad Sci U S A 1972; 69(4): 892-6.
  37. Veerendra Kumar MH, Gupta YK. Intracerebroventricular administration of colchicine produces cognitive impairment associated with oxidative stress in rats. Pharmacol Biochem Behav 2002; 73(3): 565-71.
  38. Moreno S, Meganini E. Immunocytochemical localization of catalase in rat brain. Soc Neurosci Abstr 1992; 18: 673.
  39. Drazkiewicz M, Skozynska-Polit E, Wanke M, Swiezewska E. The activity of antioxidant en-zymes in Arabidopsis thaliana exposed to colchicine and H2O2. Cell Mol Biol Lett 2003; 8(3): 777-81.
  40. Ghanei M, Harandi AA. Long term consequences from exposure to sulfur mustard: a review. Inhal Toxicol 2007; 19(5): 451-6.
Journal of Isfahan Medical School
Volume 28, Issue 122 - Serial Number 122
November and December 2011
Pages 1765-1773

Files

History

  • Receive Date: 28 March 2011
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics